Condition (MeSH)
Opportunistic Infections
ClinicalTrials.gov lists 215 trials for Opportunistic Infections or a narrower condition beneath it. National Institute of Allergy and Infectious Diseases (NIAID) has the most among industry and government lead sponsors, with 86.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase (log scale)
41 of the 215 trials are tagged with Opportunistic Infections itself; the rest are tagged with a narrower condition beneath it.
When did Opportunistic Infections trials start? (27)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 1/2
- Phase 2
- Phase 2/3
- Phase 3
- Phase 4
- Not applicable
- Observational
Top of scale: 5
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 5 |
| 2024 | 2 |
| 2023 | 2 |
| 2022 | 2 |
| 2021 | 4 |
| 2020 | 5 |
| 2019 | 3 |
| 2018 | 1 |
| 2017 | 3 |
| 2016 | 3 |
Showing 10 of 27 earlier years.
No forecast is made for this condition: it averages 2.2 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: 3 trials still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Opportunistic Infections trials in? (8)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 24 |
| Phase 1/2 | 4 |
| Phase 2 | 28 |
| Phase 2/3 | 1 |
| Phase 3 | 25 |
| Phase 4 | 8 |
| Not applicable | 89 |
| Observational | 36 |
How many Opportunistic Infections trials are recruiting? (7)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 5 |
| Recruiting | 8 |
| Active, not recruiting | 3 |
| Completed | 176 |
| Terminated | 8 |
Showing 5 of 7 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Opportunistic Infections trials? (14)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| National Institute of Allergy and Infectious Diseases (NIAID) | 86 |
| Pfizer | 13 |
| Hoffmann-La Roche | 8 |
| National Cancer Institute (NCI) | 6 |
| Astra USA | 5 |
Showing 5 of 14 sponsors.
Which drugs are being tested for Opportunistic Infections? (8)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| Zidovudine | 19 |
| Ganciclovir | 16 |
| Pentamidine Isethionate | 16 |
| Foscarnet | 12 |
| AMPHOTERICIN B | 10 |
Showing 5 of 8 drugs.
Interventions as named in the registry (7)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| Fluconazol | 21 |
| Isoniazida | 9 |
| Trimethoprim / Sulfamethoxazole | 9 |
| Pyrazinamide Oral Product | 6 |
| Ethambutol Oral Product | 5 |
Showing 5 of 7 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Opportunistic Infections trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Gastrointestinal | 61 | 1 |
| Infections and Infestattions | 54 | 1 |
| Metabolism and Nutrition Disorders | 54 | 1 |
| Blood and lymphatic system disorders | 28 | 1 |
| Hospital Readmission | 28 | 1 |
Showing 5 of 10 adverse events.
Which publications cover Opportunistic Infections? (298)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Phase 2, Randomized, Double-blind, Placebo-controlled Study of Fiztasovimab (NPC-21) for Kidney Transplant Recipients at High Risk of Cytomegalovirus Infection (LionHeart21). | Transplantation | 2025 | Yes |
| Etrasimod for the Treatment of Ulcerative Colitis: Analysis of Infection Events from the ELEVATE UC Clinical Programme. | Journal of Crohn's & colitis | 2024 | Yes |
| Tofacitinib for the Treatment of Ulcerative Colitis: An Integrated Summary of up to 7.8 Years of Safety Data from the Global Clinical Programme. | Journal of Crohn's & colitis | 2023 | Yes |
| Reappraisal of Idiopathic CD4 Lymphocytopenia at 30 Years. | The New England journal of medicine | 2023 | Yes |
| Virus-Specific T-Cell Therapy for Viral Infections of the Central Nervous System: A Review. | Viruses | 2023 | Yes |
Showing 5 of 298 publications.
Sub-conditions in MeSH (2)
MeSH descendants one level down with at least one trial, most trials first.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: prevalence and rare-disease identity.